In prostate cancer, USP33 overexpression prevents the degradation of the phosphatase dual-specificity phosphatase 1 (DUSP1), impairing c-jun N-terminal kinase (JNK) activation and apoptosis, which contributes to docetaxel resistance [40]. Here, DUSP1 is linked to prostate cancer.